Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
People's Republic of China
File

China: HG302 trial for Duchenne muscular dystrophy

This dossier follows clinical data and safety questions surrounding HG302, an experimental gene-editing therapy for Duchenne muscular dystrophy, distinguishing molecular activity, clinical benefit and adverse effects.

Last updated : 1 key moments
Illustration of a DNA double helix.
DNA representation, 2016 illustration. This does not show a participant or the therapy studied. PublicDomainPictures, CC0. — PublicDomainPictures / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — illustration de 2016, sans modification.

Where things stand

On 27 October 2026, new accounts detailed a Cell study involving four boys: molecular activity was reported alongside a treatment-related fatal event. Available evidence leaves major limits on clinical benefit and safety.

Reported information

Duchenne gene-editing trial in China highlights fatal safety risk

A Nature analysis published on 27 October 2026 examined results from a trial of HG302, developed by Shanghai-based HuidaGene for Duchenne muscular dystrophy. The study described gene-editing activity and a treatment-related death among four participants.

Illustration of a DNA double helix.
DNA representation, 2016 illustration. This does not show a participant or the therapy studied. PublicDomainPictures, CC0. — PublicDomainPictures / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — illustration de 2016, sans modification.

HuidaGene reported evidence of editing at target genes and dystrophin expression in muscle. These molecular observations do not establish a lasting clinical benefit.

Nature highlighted limited efficacy and difficulties in selecting doses. The company acknowledged limits in preclinical models' ability to predict severe immune toxicity after systemic delivery of the viral vector.

The publication adds details about a death announced in August; it does not describe a new death on 27 October. Three participants remain in long-term follow-up, HuidaGene said.

Sources 3